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Abstract
Background. Diabetic patients on hemodialysis are at high risk of death from cardiovascular
disease, and research has suggested that various biologic markers of inﬂammation, oxidative
stress and hemostasis may give added value to clinical information for predicting cardiovascular
event (CVE)-free survival. This information could be particularly important in evaluating this popu-
lation for renal transplant, given the scarcity of organs. We hypothesized that in diabetic patients
undergoing renal replacement therapy (RRT) these biologic markers would prove useful in predict-
ing event-free follow-up in a prospective study.
Methods. One hundred and ﬁfty diabetic (76 type 1, 74 type 2) and 27 non-diabetic stable RRT
patients were followed for 0.04–13.69 years for CVE (myocardial infarction, coronary arterial inter-
vention, peripheral arterial bypass or amputation, cerebrovascular accident or carotid artery inter-
vention), cardiac and all-cause mortality. Measured biologic markers of inﬂammation included the
following: Il-6, C reactive protein, ﬁbrinogen; of hemostasis: ﬁbrinogen, plasminogen activator
inhibitor (PAI), ﬁbrinolytic activity, von Willebrand factor VII (vWF), platelet-selectin, viscosity and
of oxidative stress: advanced glycated end products and antibody to oxidized low-density lipopro-
tein. For each, upper versus lower tertiles were compared for duration of event-free follow-up.
Results. Cardiovascular events prior to study entry occurred in 51.3% of DM1, 54.0% of DM2 and
25.9% of DM0 patients. Subsequent cardiovascular events were noted in 31.6% of DM1, 45.9% of DM2
and 11.1% of DM0 patients. All mean levels of biologic markers at baseline were abnormal (P < 0.05).
Conclusions. In this RRT population, all biologic marker levels except PAI did not improve clinical pre-
diction of events.
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Introduction
The rate of death on dialysis for diabetic patients remains
higher than if those patients received a renal transplant.
But clinicians lack good markers to help predict such
events and risk assess patients ahead of transplantation.
Recent trials designed to assess atherosclerosis risk in the
community have suggested that evaluation of multiple
biologic markers may not only risk stratify diabetic patients,
but also give information about the pathogenesis of cardio-
vascular events (CVEs). In an effort to risk assess patients
who were considered stable while undergoing some form
of RRT, we endeavored to determine whether biomarker
risk assessment in this population could supplement infor-
mation already available to the clinician.
In a prior study of diabetic and non-diabetic individuals
on RRT, we evaluated relationships between prior cardio-
vascular events (PCVE) and plasma markers for acceler-
ated hemostasis, heightened inﬂammatory response as
well as pathologic degrees of oxidative stress [1]. In the
current presentation, we focused on the relationships
between levels of biologic markers and subsequent cardi-
ovascular event (SCVE)-free follow-up in clinically stable
diabetic patients already initiated on RRT. We hypoth-
esized that measurement of these biologic markers would
supplement clinical evaluation in stratifying the likelihood
of CVE-free survival in the run up to renal transplantation.
At the time that this study was begun, usefulness for each
biomarker selected in predicting cardiovascular outcomes
in several other patient populations had been reported.
Patients and methods
Enrollment
The protocol and informed consent were approved by the
appropriate Institutional Review Boards. Clinically stable
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patients in the participating hospital and freestanding
dialysis units were requested to donate baseline blood
samples prior to a routine dialysis treatment. The investi-
gative biologic markers were tested only once. History of
myocardial infarction, cerebrovascular accident or inter-
vention for coronary, carotid or peripheral arterial obstruction
was recorded. Requirement for, and class of antihypertensive
drugs was recorded for a subset of patients.
Stable hemodialysis (HD, n = 128), peritoneal dialysis
(PD, n = 22) and renal transplant (RT, n = 27) patients were
enrolled in this prospective longitudinal study. The prime
focus of this analysis was the 150 diabetic patients, in-
cluding 76 with type 1 diabetes (DM1) and 74 with type 2
diabetes (DM2). Another 27 patients without diabetes
(DM0) are listed separately in the tables for comparison.
Patients were enrolled from March 1996 until March 2000.
Follow-up continued until 15 July 2010 for prespeciﬁed
end points that included myocardial infarction, coronary
artery intervention, peripheral ischemia with bypass or
amputation surgery, cerebrovascular accident or carotid
artery intervention, cardiac and all-cause mortality. End
point event adjudication was based on review of medical
records by JAD and LAW and included time to initial
thromboembolic event or death (cardiovascular and non-
cardiovascular). For analysis of time to initial event, sub-
jects lost to follow-up were censored at the time of their
last documented clinical visit. Follow-up of patients who
received a kidney transplant during the study was con-
cluded at that time. Thus, by design, CVE-free follow-up is
understated. Information retrieved from the Social Secur-
ity Death Index was considered valid for end point with
default cause of death listed as ‘unknown’.
Laboratory methods
Fibrinogen levels were determined by measuring clotting
times [2]. High-molecular weight ﬁbrinogenwasmeasured
using ethylenediamine tetraacetic acid (EDTA) plasma.
Low-molecular weight (LMW) ﬁbrinogen required the
addition of thrombin, calcium and magnesium [3]. Factor
VII antigen was determined from citrated plasma by immu-
noassay [enzyme-linked immunosorbent assay (ELISA)]
using a commercially available kit (Asserchrom VII: AG Diag-
nostica STAGO, 5 Century Drive Parsippany, NJ 07054).
Antigen levels of tissue plasminogen activator inhibitor
(PAI-I) were determined from citrated plasma by immu-
noassay (ELISA) using kits (Biopool International, 6025
Nicolle St., Ventura, CA 93003). Von Willebrand factor (vWf)
was measured in EDTA plasma by an immunoassay (ELISA)
as described by Penny et al. [4]. Fibrinolytic activity was
quantiﬁed from citrated plasma in euglobulins (ﬁbrin plate
method) [5]. C-reactive protein antigen (CRP) was deter-
mined by enzyme immunoassay using kits [UPI-Magiwell
(United Biotech, Inc.) 110 Pioneer Way, Mountain View, CA
94041-1517]. Plasma viscosity was measured using a
Brookﬁeld digital viscometer (Cone/Plate Model DV-11).
Levels of advanced glycated end products (AGEs) were
measured in plasma by immunoassay (ELISA) using polyclo-
nal antibodies to AGE-modiﬁed proteins (Picower Institute,
Manhasset, NY) [6]. Antibodies to oxidized low-density lipo-
protein (LDL) were measured by enzyme immunoassay
[ELISA (ALPCO Diagnostic PO Box 451, Wingham, NH
03087)]. Platelet (P)-selectin was determined by immu-
noassay (ELISA) using kits (Aymed Lab, Inc., 458 Carlton
Court, San Francisco, CA 94080). Interleukin-6 (IL-6) was
measured in EDTA plasma by immunoassay (ELISA) using
kits (Quantikine HS; R&D Systems, Minneapolis, MN).
Statistical methods
Comparisons of group data included analysis of individual
types of RRT individually within the presence, type or
absence of diabetes. Dialysis patients were considered
under entry mode of treatment throughout the entire
course of study.
The Kaplan–Meier function was utilized to estimate
years of event-free follow-up. Since the median of such
functions is considered the preferred measure for cen-
sored data, the medians and 95% conﬁdence limits are
reported. Comparisons of median follow-up times from
function curves between the ﬁrst and third tertiles were
tested for signiﬁcance using the log-rank test [7].
Frequency data were tested for signiﬁcance using the
Fisher’s exact test (two tailed) since some expected fre-
quencies were ﬁve or less. Study group means were com-
pared using the general linear models procedure followed
by Duncan’s multiple range test. Differences between bio-
marker means for DM1 + 2 versus DM0 and PCVE no versus
PCVE yes were tested for signiﬁcance using unpaired
t-tests. Measurement data are expressed as means with
standard error of the mean as measure of dispersion. An
alpha level less than or equal to 0.05 was considered stat-
istically signiﬁcant. Analyses were done using SAS soft-
ware, Version 8·2 (SAS Institute, Inc., Cary, NC).
Role of the funding source
Neither Amgen nor the Pat Covelli Foundation had any
role in the study design, collection or analysis of data,
preparation of the manuscript or decision to submit it for
publication. The corresponding author had access to all
the data and ﬁnal decision to submit the manuscript for
publication.
Results
Table 1 lists CVEs recorded prior to enrollment (PCVE) as
well as subsequent to enrollment (SCVE) in the study.
When classiﬁed according to type of DM, 31.6% of DM1,
45.9% of DM2 and 11.1% of DM0 subjects experienced an
SCVE. With respect to SCVE when classiﬁed according to
Table 1. Baseline demographics, PCVE and SCVEs for 177 RRT patients by
diabetic patient type deﬁned as type 1 (DM1), type 2 (DM2) or non-diabetic
(DM0)
DM0 DM1 DM2 Total DM
Baseline (n) 27 76 74 150
Age (years)a 59 ± 3.4 43.3 ± 1.0 64.6 ± 1.1
Gender (f/m) 10/17 33/43 40/34 73/77
PCVE (+/0) 7/20
(26%)
39/37
(51%)
40/34
(54%)
79/71
(53%)
During follow-up:
No event 12 24 21 45
Transplant 7 26 5 31
CVevent (+/0) 3/24
(11%)
24/52
(32%)
34/40
(46%)
58/92
(37%)
Deaths
CV 2b 2b 2b 4b
Non-CV 5 1 1 2
Unknown 0 1 1 2
Lost to follow-up
(%)
8 (29.6) 14 (18.4) 18 (24.3) 40 (26.7)
aDM2 > DM0 > DM1, P < 0.05.
bIncluded in CVevents.
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mode of RRT at baseline, 33.6% of HD, 18.2% of PD and
51.9% of RT study subjects experienced an SCVE. Duration
of follow-up was longest in the RT subset.
Table 2 demonstrates that the mean levels of factors for
hemostasis, inﬂammation and oxidative stress for all renal
failure patients were outside of the normal range (all
P < 0.05).
Table 3 incorporates PCVE (yes versus no) into a
summary of RRTand diabetes categories. HD patients with
diabetes demonstrated no differences in the level of bio-
logic markers for accelerated hemostasis, heightened
inﬂammatory response or pathologic degrees of oxidative
stress. Further analysis of the PAI-1 results is demon-
strated in Table 4. In the type 1 diabetic group, normal-
range levels of PAI-1 were associated with a 14-fold longer
event-free follow-up than low-range levels. In the type 2
diabetic group however, depressed levels of PAI-1 were
associated with a 10-fold longer event-free follow-up.
In those for whom data were available, serum albumin,
cholesterol, age, body mass index and body surface area
did not demonstrate a signiﬁcant relationship with event-
free follow-up.
Discussion
We hypothesized that the chosen biologic markers would
supplement clinical evaluation in stratifying diabetic
patient likelihood of CVE-free follow-up in the run-up to
renal transplantation. A prior history of CVEs in the
patients in this study has recently been shown to be a
poor predictor for the likelihood of future CVEs in diabetic
patients who remain stable while undergoing RRT [8].
Identiﬁcation of increased risk for the diabetic patient re-
quiring RRT might enhance or direct therapy, much as the
identiﬁcation of asymptomatic severe coronary artery
disease has led to directed intervention and improved sur-
vival [9, 10]. We had anticipated that, in this prospective
longitudinal study, knowledge of biologic markers in study
patients identiﬁed by prior medical history [1] would
permit us to assess future risk. Our pilot study demon-
strated that virtually all biologic markers of inﬂammation,
hemostasis and oxidative stress did not predict future
CVEs in a high-risk population without a previous history
of CVEs and are apparently of no use in directing therapy.
We found contradictory results for PAI-1, which may be
related to the presence or absence of insulin resistance.
Further studies on larger numbers of both type 1 and type
2 diabetic renal failure patients with objective hard cardio-
vascular end points are needed to conﬁrm our obser-
vations. As adipose tissue is able to synthesize PAI-1, it is
likely that type 2 diabetic patients will have high levels. We
suspect that very low levels of PAI-1 may be associated
with a different form of vascular pathology within athero-
sclerotic plaque [11].
In addressing this question, the Bypass Angioplasty Re-
vascularization Investigation type 2 Diabetes trial found
that patients treated with an insulin-sensitizing regimen
(thiazolidinediones or metformin) had a 15% lower con-
centration of PAI-1 than those treated with an insulin-
stimulating regimen (sulfonylurea or meglitinide). Higher
levels of PAI-1 and hence insulin resistance were associ-
ated with a greater need for revascularization [12]. The
current ﬁnding of signiﬁcantly shorter median event-free
follow-up times, when PAI levels are elevated in the type 2
diabetic group without PCVE potentially conﬁrms and
extends this observation, meriting further study.
Concentrations of PAI-1 appeared to have statistically
signiﬁcant relationships with event-free follow-up only in
DM1 subjects with PCVE and in DM2 subjects without
PCVE. For DM1 the best (longest) median event-free
follow-up times occurred in the highest tertile of PAI-1
results (approximately normal range) and the worst
(shortest) in the lowest tertile (Table 4). For DM2, the best
(longest) median event-free follow-up times occurred in
the lowest tertile (approximately normal range) and the
worst (shortest) in the highest tertile (Table 4). This ﬁnding
is hypothesis generating and further study will be needed
to understand why higher levels of a prothrombotic
marker in Type 1 diabetic patients and lower levels in Type
2 diabetics were similarly associated with better event-
free outcomes.
Our prior studies of DM1 early nephropathy subjects de-
monstrate that PAI levels rise from very low toward the
normal range with improved glycemic control using inten-
sive insulin therapy (plus ACE inhibition) [13]. These
results demonstrate stabilized renal function [14] associ-
ated with less aggressive inﬂammatory response [15] and
more efﬁcient carbohydrate oxidation [16].
Advanced glycation end products are excreted by func-
tioning native kidneys. Initiation of dialysis in the non-dia-
betic population is usually due to pure renal dysfunction
and thus AGE levels may be high. Initiation of dialysis in
Table 2. Baseline biologic marker values (means ± SEM) for the HD, PD or RT RRTpatients by diabetes mellitus type
Patients Normals
DM0 DM1 DM2 Total DM
27 76 74 150
Viscosity (plasma) 1.24 ± 0.003 centipoise 1.26 ± 0.01 1.27 ± 0.01 1.26 ± 0.01 1.28 ± 0.01
Fibrinogena 276 ± 30 mg/dL 363 ± 22 399 ± 12 416 ± 14 407 ± 9
LMWa 48 ± 10 85 ± 11 99 ± 5 108 ± 7 103 ± 4
% degrade 23.0 ± 2.2 24.6 ± 1.1 25.5 ± 1.0 25.0 ± 0.8
Fibrinolytic activityb 120.0 ± 0.9 mm2 54.4 ± 4.3 76.5 ± 5.3 67.2 ± 7.3 71.9 ± 4.5
PAI-1 25.8 ± 0.3 ng/mL 19.1 ± 1.9 17.6 ± 1.5 18.5 ± 1.3 18.0 ± 1
Factor VII 93.4 ± 0.9% 112.0 ± 3.6 113.0 ± 1.8 114.1 ± 2.3 113.5 ± 1.4
vWf 102 ± 6% 167 ± 11 191 ± 7 176 ± 7 183 ± 5
P-selectinb <100 ng/mL 157 ± 14 207 ± 13 184 ± 13 196 ± 9
IL-6 <5.6 pg/mL 17.9 ± 4.2 19.3 ± 3.4 23.9 ± 4.5 21.6 ± 2.8
CRPc <2000 ng/mL 5852 ± 928 5327 ± 609 7809 ± 752 6533 ± 491
AGE <10 IU 18.4 ± 1.7 15.9 ± 1.5 16.2 ± 1.0 16.1 ± 0.8
Ox LDL (antibody)b 275 ± 25 mU/mL 413 ± 92 1041 ± 176 788 ± 153 914 ± 117
aDM2>DM0, P < 0.05.
bDM1>DM0, P < 0.05.
cDM2>DM1, P < 0.05.
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the diabetic population may be for cardiorenal dysfunc-
tion. Thus in the diabetic population, a low AGE may indi-
cate that there is some residual renal function with
associated decrease in cardiac function. These ﬁndings
are consistent with those of Schwedler et al. [17].
Twenty years ago, in a small study of diabetic hemodia-
lysis patients (n = 100), we reported a signiﬁcant differ-
ence in all-cause mortality for calculated LDL cholesterol
above versus <2 mmol/L [18]. This year, in a large study
(n = 800 000), Tonetti et al. found direct measurement of
LDL-C to be progressively less reliable as an indicator of
acute myocardial infarction as renal function diminished
to a level requiring dialysis [19]. Since cardiac events are
more common than fatal events, it is not likely that LDL
cholesterol would have a statistically signiﬁcant impact
upon a composite of SCVEs.
Many newer biologic markers have been suggested [20]
for populations at risk for cardiovascular events, including
highly sensitive troponins, natriuretic peptides, apolipo-
proteins, homoarginenine, homocysteine, adrenomedul-
lin, carboxymethyl lysine, asymmetric dimethylarginine,
ﬁbroblast growth factors and fetuin assays. The challenge
is to identify biologic markers that add to what is known
clinically and provide insight into mechanisms of risk.
Investigators analyzing data from the German Diabetes
and Dialysis Study (4D), for example, recently reported a
correlation between low levels of homoargenine and
sudden cardiac death and heart failure in diabetic patients
on dialysis [21]. Other recent investigations [22] serve,
however, to remind us that biologic marker manipulations
(as surrogate end points) are expensive, and not necess-
arily predictive of beneﬁcial healthcare outcomes.
Limitations
We focused upon patients who had been on RRT for varied
amounts of time and simulated the population that one
sees in dialysis units. This does not reﬂect a population
that is initiating RRTor a population with renal dysfunction
at the time of AV ﬁstula creation. Our study design re-
quired hard end points and thus our results understate
the incidence of peripheral vascular disease in the diabetic
RRT community. We did not include claudication, bruits,
ankle brachial index, color change or surgeries related to
hemodialysis vascular access. Our results also understate
the prevalence and impact of angina and congestive
heart failure or transient ischemic episodes in this popu-
lation. Truncating event-free survival at the date of last
follow-up and at transplantation by design underesti-
mated event-free survival in our study population. Among
150 diabetic renal failure patients, no hard end point oc-
curred in 45 and the censoring event in 31 patients was a
new kidney transplant. Since a large percentage of
patients underwent transplantation during the course of
the study, we repeated the analysis without censoring
these patients to other prespeciﬁed end points. Although
this analysis increased the mean duration of follow-up,
Table 3. Biologic markers and PCVE: relationship to SCVE
Tertile 1 Tertile 3
Variable PCVE n Level Median 95%CL n Level Median 95%CL P-value
Viscosity 0 20 <1.23 2.3 1.5–6.0 19 >1.31 1.5 1.1–5.2 0.3868
+ 21 <1.23 1.7 0.9–2.2 19 >1·33 2.0 0.6–3.6 0.3961
Fibrinogen 0 23 <330 2.4 1.7–5.2 24 >438 1.5 1.1–3.7 0.1237
+ 26 <372 2.2 0.8–3.3 27 >446 2.0 1.5–3.1 0.4567
LMW ﬁbrinogen 0 24 <69 2.3 1.3–6.4 24 >110 1.6 1.4–4.2 0.3667
+ 25 <80 2.2 1.4–3.3 27 >120 3.1 1.5–3.6 0.6451
Fibrinogen degradation 0 25 <19.88 1.5 1.0–3.7 25 >27.51 2.0 1.4–4.2 0.8641
+ 26 <20.4 2.0 1.4–3.3 28 >28.62 2.2 0.9–3.4 0.8057
Fibrinolytic activity 0 22 <42 1.8 1.3–3.7 23 >72 2.3 1.4–4.3 0.7790
+ 25 <42 2.2 0.8–4.0 25 >90 1.9 0.8–2.3 0.5265
PAI 0 21 <10.7 4.3 1.4–6.0 21 >17.3 2.0 0.4–4.2 0.4263
+ 25 <12.3 1.5 0.6–2.2 25 >21·6 3.0 1.2–8.4 0.0134
Factor VII 0 21 <108.2 3.6 0.7–6.0 22 >118.2 2.3 1.5–4.3 0.8806
+ 25 <104.4 1.9 1.0–3.6 26 >119.7 2.2 1.2–4.0 0.6861
vWf 0 22 <138.9 3.7 1.5–6.0 22 >170.6 2.2 1.1–5.0 0.2573
+ 25 <158.8 2.2 0.8–5.6 26 >222.2 2.0 0.8–3.6 0.5326
P-selectin 0 21 <130 1.9 1.1–4.3 23 >205 2.6 1.4–5.5 0.3034
+ 25 <142 2.2 1.2–3.3 27 >186 3.4 1.5–6.7 0.5666
IL-6 0 24 <6.1 2.4 1.1–5.2 24 >12·6 2.2 1.3–3.7 0.3346
+ 26 <16.5 1.9 1.4–3.3 26 >16·5 1.9 1.4–3.3 0.6357
CRP 0 21 <1533 4.3 1.8–6.4 22 >4113 1.4 1.1–3.7 0.3039
+ 25 <3664 1.9 1.0–3.6 26 >10 482 2.3 1.7–3.6 0.7294
AGE units 0 14 <12.5 1.4 0.3–2.2 16 >21.25 2.6 1.5–4.2 0.0888
+ 18 <12.5 1.9 0.3–2.2 20 >16.25 2.7 1.5–5.6 0.0463
Ox LDL 0 21 <330 2.0 1.1–3.7 23 >605 2.3 1.5–5.2 0.3515
+ 22 <305 1.5 0.8–2.2 23 >540 2.2 0.9–3.3 0.5717
Data for all RRT-treated diabetic patients, (n = 150). Comparison of median event-free follow-up times for tertiles 1 and 3 and 95% conﬁdence limits.
Table 4. Event-free survivals for the HD, PD and RTcombined group for
tertile comparison of PAI
Biologic
marker DM PCVE Tertile n Value Median 95% CI P-value
PAI-1 1 0 1 11 <9.1 2.3 1.0–6.4
3 12 >13.7 2.6 1.4–9.0 0.2595
+ 1 12 <10.9 0.6 0.2–3.6
3 12 >22.2 8.9 7.8–10.7 0.0020
PAI-1 2 0 1 9 <11.9 4.3 2.4–8.7
3 10 >19.7 0.4 0.1–3.6 0.0307
+ 1 12 <13.6 1.9 1.5–2.2
3 13 >20.9 2.0 0.6–3.3 0.4971
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the results were quite similar in that the biologic markers
that we had chosen were not helpful.
Conclusion
Our study demonstrates that biologic markers alone are
not sufﬁcient for stratifying the risk of CVEs in a stable dia-
betic population undergoing renal replacement therapy
(RRT). This further illustrates the difﬁculties of decision-
making for physician treating diabetic end-stage renal
failure patients. The prevalence of cardiovascular disease
is high, and neither patient history [8] nor biologic
markers found helpful in lower risk populations are sufﬁ-
ciently predictive of risk in this population. Our results
should point clinicians away from the use of many expens-
ive tests for diabetic patients on dialysis to guide preopera-
tive evaluations. Our ﬁndings will require conﬁrmation in
larger studies. PAI-1 may hold out promise as a predictive
biologic marker and inhibition of PAI-1 a target for therapy
[23], but its relationship to insulin resistance must be
further investigated and understood before it has any use
as a predictor of future CVEs in a diabetic population on
dialysis.
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